Pay in 4 interest-free payments of $5.59 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
To view or add a comment, sign in Every Mechanism Has a Safety Story The more I study LDL-lowering drugs, the more I realize each one has its own safety story
Failed Attempts: Multiple drugs (Selonsertib, Cenicriviroc, Elafibranor) failed Phase 3 NASH trials because they: Targeted single pathways (inflammation or fibrosis) Didn't address root cause (obesity, insulin resistance) Showed biomarker improvements but not biopsy-proven NASH resolution Retatrutide's Advantage: Addresses root metabolic dysfunction (28.7% weight loss) Proven up to 82.4% liver fat reduction (Phase 2a) Inflammation resolution (enzyme normalization) Multi-pathway hepatic benefits Probability of Success: Higher than previous NASH drug candidates, but biopsy-proven efficacy still needs confirmation
Small, frequent meals keep the stomach from overloading while maintaining adequate caloric and nutritional intake
You can reach our customer support team by email at [email protected]
US$ 20.97
US$ 29.12
US$ 26.47
US$ 26.35
US$ 21.51
US$ 20.49
